103ACTIVITIES
7ORGS REPRESENTED
21BILLS
Revolving door — covered positions
Federal positions Cheryl held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.
Shared employee, Ofc of the Speaker & Ofc of VA 07
Sr Policy Adv, Maj Leader, Rep. Cantor
Sr Policy Adv, Republican Whip, Rep. Cantor
Sr Policy Adv, Majority Whip, Rep. Blunt
Prof Staff House Committee on E & C
Sr LA to Rep. Cox
Organizations represented
7Orgs whose LD-2 filings list Cheryl as an active lobbyist, sorted by activity volume.
Pharmaceutical Research and Manufacturers of America (PhRMA)45 activitiesCrossroads Strategies, LLC36 activitiesAdvamed:advanced Medical Technology Association15 activitiesAmerican Association of Colleges of Osteopathic Medicine3 activitiesCoalition for 1099-K Fairness2 activitiesThe Boeing Company1 activityAlabama Institute for Deaf and Blind1 activity
Bills they file on
21S. 89111 mentions
S. 52711 mentions
S. 104011 mentions
S. 104111 mentions
S. 109711 mentions
S. 109511 mentions
S. 109611 mentions
H.R. 149210 mentions
S. 83210 mentions
H.R. 53436 mentions
H.R. 71484 mentions
H.R. 23143 mentions
S. 27153 mentions
H.R. 38853 mentions
S. 39893 mentions
+ 6 more bills referenced in their activities
Topics in Filings
52Policy topics Cheryl files on across all their LD-2 activities.
Drug pricing×22
General education about biomedical research and support for scientific funding×18
FY2027 Departments of Labor×17
Health and Human Services, and Education, and Related Agencies Appropriations×17
Inflation Reduction Act×12
340B drug discount program×11
Importation of biopharmaceuticals×11
International pharmaceutical supply chain×11
PBM reform×11
TRICARE Pharmacy Program×11
Pandemic and All-Hazards Preparedness Act×11
Bipartisan Health Care Act×11
Show all 52 topics (+40 more) ▾
Prescription Pricing for the People Act×11
Drug Competition Enhancement Act×11
Affordable Prescriptions for Patients Act×11
Interagency Patent Coordination and Improvement Act×11
Stop STALLING Act×11
Preserve Access to Affordable Generics and Biosimilars Act×11
General issues×11
Medicare Part B reimbursement×11
Valued-Based Payments×11
Biopharmaceutical innovation and patent policy×11
Bayh-Dole march-in rights policy×11
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×10
FY2027 Agriculture×10
Rural Development×10
Food and Drug Administration, and Related Agencies Appropriations×10
CMMI Drug Pricing Demonstration Programs×10
EPIC Act×10
Section 232 tariff investigation on branded pharmaceuticals×10
Reimbursement issues×6
General education to advance policies×6
Discussions regarding implementation×3
Impacting third party repair of medtech×3
Medicare-funded Graduate Medical Education×3
Osteopathic Funding and Representation×3
FAIR Act×3
Community TEAMS Act×3
FY2027 National Defense Authorization Act×3
Legislative issues×2
One Big Beautiful Bill Act×2
Saving Gig Economy Taxpayers Act×2
SNOOP Act×2
Red Tape Reduction Act×2
Antimicrobial resistance×1
Insulin price cap×1
Full-Year Continuing Appropriations and Extensions Act, 2025×1
FY2025 Budget Resolution×1
FY2025 Budget Reconciliation Process×1
All bio-pharmaceutical related provisions×1
Education funding and labor issues×1
FY2026 Departments of Labor×1
Issue mix
LDA general-issue codes weighted by activity count.
Medicare/Medicaid20
Health Issues17
Trade (domestic/foreign)14
Pharmacy12
Budget/Appropriations11
Copyright/Patent/Trademark11
Medical/Disease Research/Clinical Labs6
Science/Technology6
Defense3
Taxation/Internal Revenue Code2